Eversept Partners’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-77,944
Closed -$13.7M 124
2025
Q4
$13.7M Buy
77,944
+26,179
+51% +$4.28M 0.69% 36
2025
Q3
$7.25M Buy
+51,765
New +$7M 0.5% 43
2023
Q2
Sell
-153,774
Closed -$42.8M 74
2023
Q1
$42.8M Buy
153,774
+16,426
+12% +$4.55M 2.98% 10
2022
Q4
$38M Buy
137,348
+77,204
+128% +$21.8M 3.33% 10
2022
Q3
$16.1M Sell
60,144
-41,270
-41% -$8.76M 1.39% 16
2022
Q2
$20.7M Buy
101,414
+23,411
+30% +$4.79M 1.47% 16
2022
Q1
$16.4M Buy
78,003
+44,962
+136% +$9.78M 1.26% 24
2021
Q4
$7.93M Buy
+33,041
New +$8.5M 0.51% 51

Other funds holding BIIB

Eversept Partners's BIIB Position: Q1 2026 in Review

Eversept Partners sold out of Biogen (BIIB) in Q1 2026, closing a stake of 77,944 shares — an estimated $13.7M sold.

Eversept Partners first reported a position in BIIB in Q4 2021 and held it in 8 quarters. The position peaked at $42.8M in Q1 2023. 1,009 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Eversept Partners reported no remaining Biogen position as of Q1 2026 after selling out during the quarter.
  • Eversept Partners sold 77,944 Biogen shares in Q1 2026, an estimated $13.7M.
  • Eversept Partners first reported a position in Biogen in Q4 2021 and held it in 8 quarters.
  • Eversept Partners's Biogen position peaked at $42.8M in Q1 2023.
  • 1,009 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.